The study analyzed different levels of regulating molecules for 20 hospitalized patients, 15 outpatients and 15 control subjects in 10 Spanish hospitals during the first pandemic wave in July and August 2009.
Researchers from the Hospital Clinico Universitario de Valladolid in Spain and the University Health Network found high levels of a molecule called interleukin 17 in the blood of severe H1N1 patients, and low levels in patients with the mild form of the disease.
Interleukin 17 is produced by the body and is important in the normal regulation of white blood cells which fight infection and disease. In certain circumstances, the molecule becomes "out of control", leading to inflammation and autoimmune diseases. The research paper titled, "Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza" is published in the December issue of the Journal of Critical Care.
"In rare cases, the virus causes lung infections requiring patients to be treated in hospital. By targeting or blocking TH17 in the future, we could potentially reduce the amount of inflammation in the lungs and speed up recovery," says Dr. David Kelvin, the leader of the Canadian team, Head of the Experimental Therapeutics Division, Toronto General Hospital Research Institute, University Health Network and Professor of Immunology, University of Toronto. Dr. Kelvin added that the clinical applications of this work is still many years away.
Dr. Kelvin did note, however, that a test to determine who has high levels of the molecule is possible in the near future. "A diagnostic test could let us know early who is at risk for the severe form of this illness quickly," he said, adding that high levels would indicate a failure of the immune system to eliminate the virus, similar to what happened during the 1918 Spanish flu when huge numbers of deaths occurred due to a deadly influenza A virus strain of subtype H1N1.
Dr. Jesus Bermejo-Martin, the coordinator of the Spanish team, thinks that identifying drugs able to regulate the activity of IL-17 may provide alternative treatments for patients with severe H1N1.
About University Health Network:
University Health Network consists of Toronto General, Toronto Western and Princess Margaret Hospitals. The scope of research and complexity of cases at University Health Network has made it a national and international source for discovery, education and patient care. It has the largest hospital-based research program in Canada, with major research in cardiology, transplantation, infectious diseases, neurosciences, oncology, surgical innovation, and genomic medicine. The Toronto General Research Institute has more than 350 scientists, students and support staff, more than $65 million in external funding, and its staff is published in more than 600 publications a year. University Health Network is a research and teaching hospital affiliated with the University of Toronto.
Alex Radkewycz | EurekAlert!
NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University
How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Health and Medicine
07.12.2016 | Life Sciences
07.12.2016 | Health and Medicine